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Abstract: Background: Psoriasis, a chronic inflammatory disease affecting 2–3% of the population,
is characterised by epidermal hyperplasia, a sustained pro-inflammatory immune response and
is primarily a T-cell driven disease. Previous work determined that Connexin26 is upregulated in
psoriatic tissue. This study extends these findings. Methods: Biopsies spanning psoriatic plaque
(PP) and non-involved tissue (PN) were compared to normal controls (NN). RNA was isolated and
subject to real-time PCR to determine gene expression profiles, including GJB2/CX26, GJB6/CX30
and GJA1/CX43. Protein expression was assessed by immunohistochemistry. Keratinocytes and
fibroblasts were isolated and used in 3D organotypic models. The pro-inflammatory status of
fibroblasts and 3D cultures was assessed via ELISA and RnD cytokine arrays in the presence or
absence of the connexin channel blocker Gap27. Results: Connexin26 expression is dramatically
enhanced at both transcriptional and translational level in PP and PN tissue compared to NN
(>100x). In contrast, CX43 gene expression is not affected, but the protein is post-translationally
modified and accumulates in psoriatic tissue. Fibroblasts isolated from psoriatic patients had a higher
inflammatory index than normal fibroblasts and drove normal keratinocytes to adopt a “psoriatic
phenotype” in a 3D-organotypic model. Exposure of normal fibroblasts to the pro-inflammatory
mediator peptidoglycan, isolated from Staphylococcus aureus enhanced cytokine release, an event
protected by Gap27. Conclusion: dysregulation of the connexin26:43 expression profile in psoriatic
tissue contributes to an imbalance of cellular events. Inhibition of connexin signalling reduces
pro-inflammatory events and may hold therapeutic benefit.
Keywords: psoriasis; epidermis; connexin26; connexin43; gap junction; hemichannels; connexin
mimetic peptide
1. Introduction
Psoriasis is a chronic inflammatory skin condition affecting 2–3% of the population,
characterised by epidermal hyperproliferation triggered primarily by a T-cell mediated
response, i.e., “inside-out” signalling events [1]. Environmental stresses, including a shift in
the microbiome from a commensal to opportunistic phenotype (e.g., Staphylococcus aureus),
may also play a role, i.e., “outside-in” signalling events [2–6]. Dysregulated epidermal
hyperproliferation is associated with changes in the epidermal differentiation complex.
Increased expression of the gap junction protein connexin26 (CX26), encoded by GJB2/CX26,
was first reported in psoriatic tissue in the 1990s [7,8]. More recently, RNAseq analysis
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determined that CX26 was within the top 100 genes upregulated in the psoriatic transcrip-
tome [9], however, the role of CX26 in psoriasis and differential levels of expression within
plaque border areas have not been studied in detail.
Connexins (CX) are a family of 21 highly conserved proteins that fall into discrete
phylogenetic clusters with up to 10 subtypes expressed throughout the differentiated
epidermis. Six connexins assemble to form normally closed hemichannels (HC) in the
plasma membrane, followed by intercellular alignment and docking with neighbouring
hemichannels to form intercellular gap junctions. These channels enable the exchange of
metabolites and signalling molecules throughout the avascular epidermis. CX43, encoded
by GJA1/CX43, predominates and is primarily associated with basal, proliferating layers.
CX26 and CX30 are expressed at lower amounts and localise to spinous and granular layers
in normal epidermis [10]. The connexins expressed from the GJA and GJB gene clusters are
unable to form channels with each other and, thus, the epidermal GJ expression profile is
believed to play an important role in maintaining epidermal integrity [11].
Dysregulation of connexin hemichannel signalling is a pathological trigger for a di-
verse range of disease states, including chronic non-healing skin wounds, retinopathies and
neurodegenerative disorders ([12,13]); as such, connexin channel blockers emerge as prime
therapeutic targets [12,13]. We recently reported that exposure to the pro-inflammatory
mediator peptidoglycan (PGN), isolated from S. aureus, promotes CX26 expression in
keratinocytes and ATP release, impacting downstream purinergic signalling pathways
and inflammation [10,14]. These events can be attenuated by connexin channel inhibitors,
including carbenoxolone, the connexin mimetic peptides (CMP) Gap27 targeted to the
second extracellular loop of CX43 and by siRNA targeted to CX26 or CX43 in cell model
systems [14–16].
In the present manuscript, we have uniquely used skin biopsies spanning psoriatic
plaque border regions, enabling a comparative analysis of the connexin gene and protein
expression patterns from clinically involved chronic psoriatic plaque (PP) and clinically
non-involved psoriatic border regions (PN) to be correlated with normal tissue (NN). Three-
dimensional (3D) organotypic models were also generated to gain further insight into
epidermal connexin signalling. Cytokine arrays were used to assess the pro-inflammatory
status of the 3D models grown on feeder layers of normal and psoriatic fibroblasts and the
influence of PGN and Gap27 on pro-inflammatory events. The data are discussed in the
context of diverse whole genome (WGA) and RNAseq analysis [17–20] and indicate that
altered signalling via connexin channels is a key contributor to the psoriatic state.
2. Results
2.1. Epidermal Thickening in Perilesional and Lesional Tissue
Biopsies from psoriatic patients and normal healthy donors were obtained following
ethical consent (Section 4.1) and termed normal (NN), psoriatic plaque (PP) and psori-
atic non-involved (PN) with tissue being within 1–1.5 cm from the plaque lesion border
(Figure 1a). Histological analysis confirmed that the epidermis from normal donors (NN)
was ~30 µm thick with ~5 discrete epidermal layers visible (Figure 1b,e). PN epidermis
was ~three-fold thicker (~100 µm) with rete ridges beginning to elongate, although not sta-
tistically thicker than NN samples (Figure 1c,e). PP epidermis was at least ten-fold thicker
than NN (~320 µm) and significantly thicker than PN tissue with classical histopathological
features of psoriasis including elongation of rete ridges, acanthosis and parakeratotic hy-
perkeratosis evident (Figure 1d,e). Semi-quantitative analysis of nuclei staining in dermal
layers confirmed enhanced inflammatory cell infiltrate in psoriatic tissue that was two-fold
higher for PN and four-fold higher in PP regions than NN biopsies (Figure 1f).
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Figure 1. Histological analysis of psoriatic versus normal tissue biopsies. Tissue biopsies were col-
lected from normal donors (NN), psoriatic non-involved (PN) or psoriatic plaque (PP) regions. (a) 
Diagrammatic representation of tissue biopsy sites from PP and PN locations; (b–d) representative 
images of NN, PN and PP biopsies are presented; dotted lines indicate examples of measurements 
taken; (e) epidermal thickness; (f) mean dermal nuclear infiltrate. N = 3 donors. Statistical signifi-
cance was calculated by ANOVA followed by Tukey post-hoc test *** p < 0.005, **** p < 0.0001. Bar = 
100 μm. 
2.2. Protein Expression in NN, PN and PP Tissue 
Cytokeratin 16 (CK16), a hallmark of psoriasis [21–23], was barely detectable in nor-
mal epidermal tissue (Figure 2a) and was significantly upregulated in the cytoplasm of 
PN and PP biopsies (Figure 2a). Ki67, a marker for cell proliferation [24], was also barely 
evident in NN tissue (Figure 2b), with proliferation significantly upregulated in basal lay-
ers of PN and PP biopsies (Figure 2b). CX43 was widely expressed throughout the normal 
epidermis, especially in the spinous layer (Figure 2c). The level of CX43 was significantly 
increased in psoriatic tissue (Figure 2c), particularly in the spinous layer of the PN sections 
(Figure 2c), where intracellular staining was evident compared to the PP regions where 
the protein predominantly localised to the plasma membrane (Figure 2c and in the mag-
nified images in Figure 4c,f,i). CX26 is not normally expressed at high levels in the normal 
epidermis, as confirmed in Figure 2d. In contrast, CX26 was expressed throughout the 
psoriatic epidermal tissue (PN or PP) (Figure 2d). The expanded epidermis in psoriasis 
Figure 1. Histological analysis of psoriatic versus normal tissue biopsies. Tissue biopsies were
coll cted from norm l donors (NN), psoriatic non-involved (PN) or psor atic plaque (PP) gi ns.
(a) Diagrammatic representation of tissue bi psy sites from PP and PN locations; (b–d) representative
images of NN, PN and PP biopsies are presented; dotted lines indicate examples of measurements
taken; (e) epidermal thickness; (f) mean dermal nuclear infiltrate. N = 3 donors. Statistical significance
was calculated by ANOVA followed by Tukey post-hoc test *** p < 0.005, **** p < 0.0001. Bar = 100 µm.
2.2. Protein Expression in NN, PN and PP Tissue
Cytokeratin 16 (CK16), a hallmark of psoriasis [21–23], was barely detectable in normal
epidermal tissue (Figure 2a) and was significantly upregulated in the cytoplasm of PN
and PP biopsies (Figure 2a). Ki67, a marker for cell proliferation [24], was also barely
evident in NN tissue (Figure 2b), with proliferation significantly upregulated in basal
layers of PN and PP biopsies (Figure 2b). CX43 was widely expressed throughout the
normal epidermis, especially in the spinous layer (Figure 2c). The level of CX43 was
significantly increased in pso iatic tissue (Figure 2c), particularly in the spinous layer of
the PN ections (Figure 2c), where intracellular staining was evident compared to the PP
regions where the protein predominantly loc lised o the plasm membrane (Figure 2c
and in the magnified images in Figure 4c,f,i). CX26 is not normally expressed at high
l vels in the nor al epidermis, as confirmed in Figure 2d. I contrast, CX26 was expressed
throughout the psoriati epidermal tissue (PN or PP) (Figure 2d). T e xpanded pidermis
in psor asis was also ev dent by co-staining with DAPI in each s ction, as illustra ed in
Figure 2e. The co-localisation of CX43 and CX26 was also evid nced in the expanded
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spinous layer, clearly seen in the magnified insert panel of the PP tissue, with less CX26
present in basal areas (Figure 2e). The mean fluorescent intensity (MFI) of each marker
(Figure 2a–d) is represented in the right-hand panel, confirming the profound upregulation
of protein expression in psoriatic tissue compared to normal controls.
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Figure 2. Immunohistochemistry of NN, PN and PP biopsies: frozen sections of biopsies were sectioned (7 um) and subject
to immunohistochemical analysis. Representative images for (a) CK16 (green); (b) Ki67 (green); (c) CX43 (red) and (d) CX26
(green) are presented; (e) merged images of CX43, CX26 and DAPI (blue). The right-hand panel magnified insert with
the yellow arrow indicating co-localisation areas. The white dotted line indicates tissue dge, and yellow dots i ic t
100 µm. The mean fluorescent intensity/µm2 extracted fro multiple images of three donors
for each group is indicated in the right-hand panel for each marker. Statistical significance was calculated by two-tailed
t-test * p < 0.05; ** p < 0.01.
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2.3. Gene Expression in NN, PN and PP Tissue
Expression of a panel of genes associated with connexin signalling and/or psoriasis
was assessed by real-time polymerase chain reaction (RT-PCR) of NN, PN and PP tissue
(Figure 3). Expression of CX26 was dramatically upregulated in tissue from PP regions
where gene expression was up to 20,000-fold higher than normal tissue (Figure 3). In PN
regions, CX26 expression was significantly greater than NN tissue (~5000-fold) (Figure 3)
with a similar trend for CX30 where expression was ~30-fold greater than NN tissue
(Figure 3). There was no significant change in the expression of CX43 (Figure 3) in PP
biopsies compared to NN. However, in samples taken from PN regions, CX43 expression
was enhanced two-fold (Figure 3). No biologically significant changes in Panx1 gene
expression were observed, although the level of expression in PP regions was ~two-fold
less than that in PN areas (Figure 3). The level of gene expression of Ki67 in PP or PN tissue
was no different to that of normal tissue, while the level of TLR2 and IL-17 expression was
~2.5-fold higher in PP biopsies (Figure 3). Thus, from the panel of genes examined CX26
and CX30 were consistently upregulated in psoriatic tissue, although individual levels
of expression between patient samples were highly variable, with some patients being
“superexpressors” of CX26.
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2.4. CX43 Is Post-Translationally Modified in Psoriatic Epidermis 
The data from the gene and protein expression of total CX43 suggested that upregu-
lation of CX43 was possibly due to a stall in the CX43 life cycle or a post-translational 
event [26]. The level of CX43ser368 phosphorylation in the normal epidermis was barely 
detectable, with some isolated areas of punctate staining observed (Figure 4a,b). This is in 
contrast to the extensive staining of total CX43 observed in the NN tissue (Figure 2C (NN) 
and in the magnified NN image of total CX43 staining (Figure 4c). By contrast, in PN and 
Figure 3. Gene expression profiles of NN, PN and PP biopsies. RNA was extracted from NN, PN and PP tissue biopsies
and subject to RT-PCR analysis. Results are presented as the fold change in gene expression/GAPDH compared to NN
gene expression/GAPDH. Data sets were statistically analysed by ANOVA followed by Dunnett’s multiple comparison test
comparing PP and PN samples with control (***) and PN with PP samples (##). N = 6 biopsies per patient *** p < 0.0001;
## p < 0.005; * (#) p < 0.01. The dotted line indicates a two-fold increase in gene expression considered biologically signifi-
cant [25].
2.4. CX43 Is Post-Translationally Modified in Psoriatic Epidermis
The data from the gene and protein expression of total CX43 suggested that upreg-
ulation of CX43 was possibly due to a stall in the CX43 life cycle or a post-translational
event [26]. The level of CX43ser368 phosphorylation in the normal epidermis was barely
detectable, with some isolated areas of punctate staining observed (Figure 4a,b). This is in
contrast to the extensive staining of total CX43 observed in the NN tissue (Figure 2c) (NN)
and in the magnified NN image of total CX43 staining (Figure 4c). By contrast, in PN and
PP biopsies, high levels of CX43ser368 phosphorylation was observed (Figure 4d,e,g,h). In
the PN biopsies, staining was mostly localised to the plasma membrane areas (Figure 4e)
compared to the intracellular staining observed using an antibody detecting total CX43
(Figure 4f). In PP biopsies, both CX43ser368 and total CX43 staining was predominantly lo-
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cated at plasma membrane regions indicative of gap junction plaque formation (Figure 4g–i)
Semi-quantitative analysis, expressed as the mean fluorescence intensity (MFI), from four
psoriasis patients and two controls confirmed the observed upregulation (Figure 4j).
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Frozen sections of biopsies were sectioned and stained with an antibody targeted to phosphorylated CX43ser368 (red and
DAPI blue) or an antibody targeting total CX43. Repres ntative images of N (a–c); PN (d–f) and; PP (g–i) are pres nted.
Bar = 100 µm; (j) The fold increase in mean fluorescent intensity (MFI) extracted from ultiple images of CX43ser368
staining of PN and PP biopsies over NN is represented (N = 4 donors). HaCaT cells were exposed to 10 µg/mL PGN for
15 min to 24 h followed by fixation and staining for CX43ser368 (k–m) bar = 20 µm. The MFI extracted from multiple images
of CX43ser368 staining in PGN treated samples/control is represented in (n) (N = 3). Data were statistically analysed by
one-way ANOVA followed by Dunnet’s multiple comparison analysis against relevant control (NN or 0 h) ** p < 0.005;
*** p < 0.0001).
2.5. CX43 Is Post-Translationally Modified in Keratinocytes Exposed to the Pro-Inflammatory
Mediator Peptidoglycan Isolated from S. aureus
Previously we determined that Cx-HC signalling was triggered by exposing ker-
atinocytes to peptidoglycan (PGN), stimulating downstream signalling events including
the expression of IL-6, IL-8 and CX26, and on prolonged exposure, decreased CX43 protein
expression [14–16]. This data suggests that an “outside-in” signalling route can alter con-
nexin expression profiles and function. Under basal conditions, limited phosphorylation
of CX43 was evident in HaCaT cells, a model human keratinocyte cell line (Figure 4k).
However, exposure of HaCaT cells to 10 µg/mL PGN for 15 min to 24 hours (h), induced
CX43ser368 phosphorylation (Figure 4k–n), further suggesting that pro-inflammatory
events and an “outside-in trigger” can alter CX43 phosphorylation status.
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2.6. A 3D Organotypic Model of Psoriatic Epidermis
The PGN model provides an example of an “outside-in” trigger and reflects the
changes in CX expression that occurs in the psoriatic epidermis. The functional conse-
quences contribute to purinergic signalling pathways that also play an important role in
psoriasis [14,27]. To explore these events, further 2D and 3D organotypic models utilising
primary keratinocytes and fibroblasts grown on transparent membranes were used [28,29].
In contrast to the isolation and culture of keratinocytes from normal and diabetic donors
that have been successfully used previously in this approach [29], keratinocytes derived
from psoriatic patients were difficult to passage following initial isolation. Therefore, 3D
organotypic models explored the impact of fibroblasts isolated from PP tissue biopsies
(psoriatic fibroblasts (PF)) on the stratification of normal adult primary keratinocytes (NK)
in comparison to those grown on normal fibroblast (NF) feeder layers (Figure 5a–e). In
psoriatic patient skin biopsies, RT-PCR determined that IL-6 expression levels were higher
in PP biopsies than that from NN donors (Figure 6a). Following isolation and culture of
NF and PF cells, the media was harvested and IL-6-ELISA assays determined that the
psoriatic fibroblasts had a higher pro-inflammatory status than normal adult fibroblasts
(Figure 6b). Thus, we hypothesised that this “inside-out” pro-inflammatory status would
drive an increase in CX26 expression and other changes seen in the epidermis of psoriatic
tissue. Following three weeks of culture at the air-liquid interface (ALI), cells were fixed
and keratinocytes stained in situ for CX26, CX43, Ki67, E-cadherin and CK16. When grown
on an AF feeder layer, CX26 was present in very low amounts, which was clearly increased
in the models grown on the PF feeder layer (Figure 5a). CX43 was readily detected in both
normal and psoriatic models, with evidence of CX43 expression in stratified regions in the
psoriatic model (Figure 5b). Increased Ki67 staining was observed in the psoriatic model
(Figure 5c); CK16 was equally expressed in both, while the level of E-cadherin was reduced
in the psoriatic model (Figure 5d,e). Thus, the model reflected the expression profile of
many aspects of the psoriatic epidermis, suggesting that soluble/diffusable factors released
by psoriatic fibroblasts can drive alterations in keratinocyte status.
Upon termination of the experiment, the media from the 3D cultures was harvested
and subject to a RnD cytokine array. The data from the arrays were expressed as the
fold increase in cytokine expression in the NK/PF culture to the NK/NF cultures. In
agreement with the initial ELISA assay, at the start of the experiment, IL-6 expression
was significantly higher in the psoriatic model. Increased expression of IL-8, chemokine
(C-X-C motif) ligand 1(CXCL1), macrophage migration inhibitory factor (MIF) or monocyte
chemoattractant protein 1(MCP-1) were also noted (Figure 6c). Thereby indicating that the
enhanced inflammatory status of the PF and “inside-out” signalling events were involved
in promoting the changes seen in the 3D organotypic epidermis.
2.7. The Connexin Mimetic Peptide GAP27 Reduces PGN Evoked Pro-Inflammatory Responses in
Adult Fibroblasts
To determine if PGN challenge evoked similar trends in cytokine expression seen in the
3D “psoriatic model” 2D monocultures of NF were challenged with 10 µg/mL PGN for 24 h.
An ELISA assay determined that IL-6 expression was clearly induced following challenge
(Figure 6d) and RnD cytokine arrays determined that expression of a range of cytokines
including MIF, MCP-1, IL-6, IL-8, CXCL1, granulocyte colony-stimulating factor (GCSF),
granulocyte-macrophage colony-stimulating factor (GMCSF) and chemokine ligand 5
(CCL5) were induced (Figure 6e). Previously we have shown that PGN challenge also
evoked connexin hemichannel activity and that this was related to an enhanced cytokine
response that can be inhibited by connexin channel blockers [14–16]. The connexin mimetic
peptide Gap27 has also previously been shown to inhibit Cx hemichannel activity and
enhance wound closure rates in normal adult fibroblasts and keratinocytes [30]. Exposure
of NF to Gap27 on its own had no effect on IL-6 expression (Figure 6d), however, it
significantly reduced the PGN evoked IL-6 response (Figure 6d). When applied to the
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cytokine arrays, no significant induction of cytokine expression was seen in supernatants
from cells exposed to PGN and 100 nM Gap27 (Figure 6c).




Figure 5. 3D Organotypic epidermal model. Keratinocytes grown in transwells on either a normal 
(column NK/NF) or on a psoriatic (column NK/PF) fibroblast feeder layer were fixed and stained 
after 12 days at the ALI with relevant antibodies followed by 3D z-stack reconstruction (Z: NK/NF). 
IHC analysis determined expression of (a) CX26, (b) CX43, (c) Ki67, (d) E-cadherin and (e) CK16 
protein expression. The mean fluorescent intensity of multiple regions from different cultures was 
extracted (right hand panel). Statistical analysis was performed by Student t-test N = 3. * p < 0.05; ** 
p < 0.001. 
Upon termination of the experiment, the media from the 3D cultures was harvested 
and subject to a RnD cytokine array. The data from the arrays were expressed as the fold 
increase in cytokine expression in the NK/PF culture to the NK/NF cultures. In agreement 
with the initial ELISA assay, at the start of the experiment, IL-6 expression was signifi-
cantly higher in the psoriatic model. Increased expression of IL-8, chemokine (C-X-C mo-
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Figure 5. 3D Organotypic epidermal model. Keratinocytes grown in transwells on either a normal
(column NK/NF) r on a soriatic (column NK/PF) fibroblast feede layer were fixed and stained
after 12 days at the ALI with relevant antibodies followed by 3D z-stack reconstruction (Z: NK/NF).
IHC analysis determined expression of (a) CX26, (b) CX43, (c) Ki67, (d) E-cadherin and (e) CK16
protein expression. (a–e) bar = 100 µm. The mean fluorescent intensity of multiple regions from
different cultures was extracted (right hand panel). Statistical analysis was performed by Student
t-test N = 3. * p < 0.05; ** p < 0.001.
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Gap27. (a) RNA was extracted from NN and PP tissue biopsies and subject to RT-PCR analysis to assess IL-6 gene expression
(N = 6 biopsies per patient); data are expressed as the fold ch nge in IL-6 expression compared to norm l tissue. (b) Media
was coll cted from NF and PF cells subject to ELISA assay for IL-6 (N = 6); data are expressed as the fold increas in
IL-6 protein expression compared to NF. (c) Following 12 days at the ALI and generation of the 3D organotypic model the
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compared (N = 3). Statistical analysis was performed via two-tailed t-test to determine significance compared to NN or NF
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protein expression over control was determined (N = 4). One-way ANOVA followed by Dunnett’s multiple comparison
determined the significant differences between (d) PGN challenged with control and PGN+Gap27 # p < 0.05, ### p < 0.001
and (e) within each cytokine group to the control * p < 0.05, ** p < 0.001; *** p < 0.005.
3. Discussion
In the present study, we report for the first time a detailed comparison of the gene
and protein expression profiles of CX26 and CX43 in NN, PN and PP tissue biopsies. We
conclude that enhanced CX26 is a key molecular footprint of psoriasis and that upregulation
of CX26 expression and function critically relate to pathophysiological pathways that
trigger the condition.
Within the normal epidermis, the levels of CX26 expression are barely detectable by im-
munohistochemical staining, however, in hyperproliferative skin, CX26 levels are enhanced.
This was originally reported in the 1990s in psoriatic tissue, human papillomavirus infected
warts and at the wound edge of chronic non-healing wounds [7,8,31]. In the present study,
CX26 gene expression was enhanced in all biopsies taken from psoriatic patients compared
to normal skin biopsies, with significant variation ranging from 5 to >1000-fold over normal
tissue, indicating patient variability. Extraction of data from multiple mRNAseq and WGA
from PP/PN/NN confirm that CX26 is consistently enhanced. In an initial mRNAseq
analysis, CX26 was in the top 100 genes upregulated with an 18-fold increase over normal
tissue, CX30 expression was 7-fold higher, however, no changes in expression of CX43 were
observed [9]. Psoriasis is a multifactorial disorder with a diverse array of triggers with
different forms associated with distinctive areas of the body. All biopsies in the present
study were collected from patients with chronic plaque psoriasis (CP), with tissue isolated
from trunk and pressure point areas. In a study by Ahn et al., differential gene expression
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and ingenuity pathway analysis performed on biopsies isolated from chronic plaque (CP),
scalp psoriasis (SP) or palmoplantar psoriasis (HF) [17] revealed that CX26 and CX30
were enhanced in CP and SP compared to NN tissue, in line with the present study. By
contrast, in HF, only CX30 was consistently upregulated. Studies of Chinese populations
have suggested that CX30 was a suitable biomarker for psoriasis [32–34], and in WGA
of Chinese populations, CX30, but not CX26 expression, was upregulated [19,20]. In our
study, in patients where CX26 levels were not excessively upregulated, the levels of CX30
expression tended to be higher; the relevance of this warrants further analysis in a broader
patient cohort. In the present study, CX26 and CX30 were the only markers analysed that
were consistently upregulated in all of the patient biopsies analysed.
CX26 assembles to form HC in the plasma membrane, which can release ATP into the
extracellular space prior to aligning with neighbouring hemichannels to form gap junction
units [11]. It is well established that aberrant CX26 expression and function is associated
with epidermal dysplasia [35]. In a mouse model of Cx26 overexpression, where Cx26 was
under the control of the involucrin promoter, mice developed a psoriasiform phenotype
with enhanced proliferation, inflammation and delayed wound closure response [36]. In
another model, the application of a tumour promoting agent evoked Cx26 expression [37].
Tape stripping of the normal human epidermis also induced an increase in CX26 prior to
the onset of hyperproliferation, assessed by Ki67 staining, suggesting epidermal trauma can
evoke increases in CX26 expression and may relate to HC sensitivity to mechanical stimu-
lation [8,38]. Mutations in CX26 are associated with a wide range of epidermal disorders of
differing severity, including keratitis ichthyosis deafness syndrome, an inflammatory skin
disorder with susceptibility to opportunistic skin infections and associated with “leaky”
CX26 hemichannels and altered oligomerisation profiles [11,39–41].
In single-cell mRNAseq analysis from PP and NN tissue, Cheng et al. captured
keratinocytes by laser dissection from discrete layers of the epidermis and analysed PP/NN
expression ratios in ingenuity pathways [42]. The data was extracted as the log odds
of differential gene expression between PP/NN keratinocytes that were classified into
discrete units basal, follicular, channel, mitotic, spinous, etc. The odds of CX26 and
CX30 upregulation in basal, mitotic and spinous layers was ~1000-fold. In a population of
keratinocytes enriched with channel markers the likelihood of CX26 and CX30 upregulation
was 7–8000 but CX43 or CX45(GJA5) were unlikely to be altered.
The core psoriatic pathways identified by Ahn et al. [18] included MIF innate, purine
nucleotide degradation and inflammasome activation. Overexpression and activation
of CX26 feed into each of these pathways. Although HC are normally closed, environ-
mental triggers including hypoxia and microbiome alterations open HC triggering pro-
inflammatory mediated pathways and inhibitors of HC function emerge as key therapeutic
targets for diverse inflammatory conditions [43–47]. Human CX26-HCs are predicted
to be in a constitutively open state [48]. In normal skin this may be critical where ATP
release is known to be a driver for normal cellular differentiation and calcium wave prop-
agation [38,49,50]. Upregulation of CX26, leading to both an increase in CX26-HC in the
plasma membrane and their ability to laterally accrete and dock to form Gap junctions
would also provide more CX26-HC sensitivity to mechanical stimulation [38], causing an
imbalance in epidermal signalling through the avascular epidermal layers. This would re-
sult in increased ATP release from cells, feeding into purinergic signalling pathways, a key
trigger for psoriasis and associated with activation of pro-inflammatory events and altered
differentiation pathways in the epidermis [27,51,52]. Recently we dissected these events in
HaCaT cells where PGN exposure triggered CX26 expression, HC activity, monitored by
ATP release and IL-6/IL-8 expression, events that were all controlled by inhibition of CX26
channel function, NfkB and purinergic inhibitors [14]. The presence of enhanced levels
of ATP released from cells via CX26 channels would enter purine nucleotide degradation
pathways. In the present study, we showed that the connexin mimetic peptide GAP27 that
primarily inhibits Cx43 signalling reduced PGN-evoked cytokine release in adult fibrob-
lasts that predominantly express CX43, further supporting strategies that target connexins’
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therapeutic potential for chronic inflammatory conditions [43]. Antisense technologies
targeting both Cx43 and Cx26 have reported benefits in in vivo wound healing studies, and
a recent report by Becker and colleagues suggests that preventing upregulation of CX26
reduces inflammation and epidermal thickening [53]. Further studies are now warranted
to explore if targeted inhibition of CX26 and CX30 in keratinocytes hold therapeutic benefit
for psoriasis. No change in expression of Panx1 was observed in the psoriatic biopsies
and we previously determined that PGN exposure did not alter Panx1 protein expression
levels in keratinocytes [14]. However, the activation of Panx1 channels cannot be ruled out,
particularly as activation of Panx1 is closely related to triggering the inflammasome [54,55],
a pathway identified by Ahn et al. to be central to psoriasis [17].
By contrast to the change in CX26/CX30 gene expression, no change in CX43 gene
expression was observed in the present work or in available WGA and mRNAseq data.
Furthermore, in the study by Cheng et al. on keratinocyte populations, CX43 had a low
prediction score (<30) in the channel subpopulation of keratinocytes [42] suggesting other
roles for CX43. We identified that CX43 protein expression was significantly upregulated
in psoriatic epidermal layers and that this was associated with phosphorylation of CX43
at position ser368 on the carboxyl tail. Several studies suggest that a chronic inflamma-
tory environment can alter CX43 expression. In chronic non-healing, epithelial CX43 is
dramatically upregulated at the wound edge, where both Cx mimetic peptides and SiRNA
approaches show therapeutic potential in improving wound healing and resolving inflam-
mation [30,47,56,57]. In endothelial cells, exposure to PGN rapidly evoked Cx43ser368
phosphorylation, followed by a decrease in protein expression [15]. Similarly, in HaCaT cell
models, CX43 expression was reduced following 24 h exposure to PGN with Cx43ser368
phosphorylation and redistribution of the protein to intracellular stores and perinuclear
regions evident in the present work [14]. In other recent studies, exposure of HaCaT cells
to IL-22 resulted in the loss of gap junction coupling and a decrease in CX43 expression,
although no changes in CX30 or CX26 were reported [58]. The decrease in CX43 expression
was linked to the JNK pathway but not NfKB. In contrast, in the study by Garcia-Vega
et al., the inhibition of NfKB was clearly linked to a decrease in PGN activated CX26
expression and function [14], recently reviewed by [10]. While promoter regions of CX26
have NfkB regulatory domains, these have not been associated with CX43 gene expression.
In other studies, increased IL-6 expression in systemic inflammation has been linked with
the downregulation of Cx43 expression in diverse tissues [59].
The rapid life cycle of Cx43 undergoes cyclic changes in phosphorylation profiles.
The phosphorylation status of Cx43 is critical for the removal and targeted degradation
of Cx43 [26,60]. Cx43 is rapidly removed from junctional areas upon phosphorylation
which occurs on multiple serine residues on the carboxyl-terminal tail driven by PKC, MAP
and ERK and PKA mediated events. Phosphorylated Cx43 is also targeted for ubiquitin
degradation pathways, a major pathway upregulated in CP psoriasis but not associated
with SP or HF [18]. Thus, we propose that phosphorylated CX43 is targeted for degradation
in psoriasis, which may also explain the differences in the intracellular localisation of the
protein in PP biopsies and HaCaT cells following prolonged exposure to PGN.
In the present study, we had difficulty in expanding keratinocyte cultures isolated from
psoriatic tissue compared to standard procedures used for NN keratinocytes. In contrast,
fibroblasts were readily sourced. Fibroblasts from psoriatic patients displayed a higher
pro-inflammatory index than those isolated from normal patients with markers including
IL-6, IL-8 and MIF upregulated, all of which were identified to be upregulated to different
degrees in psoriatic tissue [17,18]. 3D organotypic models of normal keratinocytes grown
on PF feeder layers developed an epidermal profile similar to that observed and reported in
psoriatic tissue. CX26 and Ki67 levels were increased with a decrease in E-cadherin protein
expression, suggesting this model could be further developed to dissect the impact of drugs
targeting connexin related pathways and environmental triggers on patho-physiological
mechanisms leading to psoriasis [61]. In a study on therapeutic modulators in psoriasis,
Shaker and colleagues assessed CX26 expression in biopsies of patients before and after the
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classical psoriatic therapies—methotrexate and PUVA [62]. In all the biopsies, CX26 was
enhanced in non-treated psoriatic tissue, with follow-up biopsies revealing decreased levels
of CX26 clearly linked to clinical improvement. It remains to be determined if the diverse
changes in CX26 gene expression plays a part in psoriasis disease severity, and whether
it is triggered by the Koebner phenomenon [63] or at mechanical stretch points, recently
suggested to trigger stimulated keratinocyte proliferation and cytokine release [64].
In conclusion, maintaining the balance of CX26:CX43 expression and function is critical
for maintaining epidermal integrity. It is evident that therapeutic pathways controlling
CX26:43 expression and channel activity hold potential. For example, current drugs in use
targeting NfKB pathways may play a role in reducing CX26 thereby decreasing aberrant
CX26 signalling helping resolve the inflammatory status that trigger hyperproliferation.
4. Materials and Methods
4.1. Biopsy Recruitment
Incisional elliptical skin biopsies (approximately 2.5 cm thick and 3 cm long) were
collected from 19 psoriatic patients following ethical consent in the Department of Der-
matology, University Hospital Crosshouse (ethical approval REF-16WS-0024, (age range
23–76)). Patients were not undergoing biologic treatments and no topical treatment was
applied to the biopsy area for 7 days prior to the biopsy being taken (Figure 1a). Biopsies
were termed psoriatic plaque (PP) and non-involved (PN) with tissue being within 1–1.5 cm
from the plaque border. Control tissue (NN) from normal healthy donors was acquired
from the GCU Skin Tissue bank (REF 16ES-0069). Tissue was collected in Dulbecco’s
Modified Eagle’s Medium (DMEM, SLS, Newhouse, UK).
4.2. Cell Culture and 3D Organotypic Model
Fibroblasts and keratinocytes were isolated from tissue biopsies as previously de-
scribed [30,65]. Briefly, subcutaneous fat was removed from tissue biopsies and tissue was
exposed to dispase (ThermoFisher, Paisley, UK) (5% w/v) overnight at 4 ◦C to separate
epidermal and dermal layers. Separated pieces of dermis were cut into approximately
1 × 1 mm2 pieces. Explanted tissue was placed in 6 well plates and overlaid with DMEM
supplemented with 10% foetal calf serum, L-glutamine (2 mM) and 100 µg/mL) peni-
cillin/streptomycin (cDMEM) (Lonza, Slough, UK), cultured at 37 ◦C/5%CO2 for 48–72 h
to adhere. Media was changed every 2–3 days until cells reached confluence when they
were washed in PBS, detached using TrypLe (Invitrogen, Paisley, UK) dissociating agent
and expanded in T75 flasks.
Fibroblasts and HaCaT cells, a model human keratinocyte cell line (CLS, Eppelheim,
Germany [66]), were cultured in cDMEM. Fibroblasts were banked at passage 1–2 or used
for up to 4 passages. Keratinocytes derived from biopsies were cultured in Epilfe-S7 Media
(Fisher Scientific UK Ltd., Loughborough, UK) and were used up to 4 passages (NK).
For the 3D organotypic model, normal (NF) or psoriatic fibroblasts (PF), isolated
from psoriatic plaque (PP) areas, were grown to confluency on 6-well plates. Normal
keratinocytes (NK) (1 × 106 cells) were seeded onto polyester transparent transwell inserts
(ThermoFisher, Paisley, UK) in EplifeS7 and media was changed every 2 days until conflu-
ency. The insert was raised to the ALI for 12 days to enable keratinocyte stratification with
600 µL media maintained in the wells beneath the transwell at all times [28,65,67].
4.3. Cell Challenges
HaCaT cells and NF were challenged with 10 µg/mL peptidoglycan (PGN) isolated
from S. aureus (Sigma-Aldrich, Irvine, UK) for 15 min to 24 h prior to harvesting media
and fixation of cells [14]. Where appropriate, cells were exposed to the connexin mimetic
peptide Gap27 (100 nM (Zealand Pharma, Glostrup, Denmark)) throughout the PGN
challenge [14].
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4.4. Histological Analysis
The tissue (1–2 mm2) was fixed in paraformaldehyde 4% (w/v) overnight at 4 ◦C,
wax embedded and stained by H&E following routine procedures. Slides were viewed
under an Axiovert 200 inverted microscope linked up to a Zeiss digital 100 camera and
images processed using ZEN 2. Blue edition software (Carl Zeiss Microscopy GmbH, Jena,
Germany) and Image J.
4.5. Immunohistochemistry
Tissue taken directly from the DMEM media (~0.25 mm2) was mounted in optimal
cutting temperature compound (OCT) (ThermoFisher, Paisley, UK) and 7 µm sections
cut onto pre-coated slides. Tissue sections, organotypic cell models or cells cultured on
16 mm2 glass coverslips were fixed in ice-cold methanol prior to permeabilisation and
blocking, as previously described [14]. The primary antibodies: rabbit polyclonal anti-Cx43
(1:100 dilution, [68]); mouse monoclonal anti-Cx26 (1:50 dilution, 13–8100, ThermoFisher,
Paisley, UK); rabbit polyclonal anti-Ki67 (1:500, Abcam, Cambridge, UK, ab15580); rabbit
polyclonal anti-cytokeratin16 (1:100; Abcam, Cambridge, UK ab53117); rabbit polyclonal
anti-Cx43pSer368 (1:100; Sigma-Aldrich, Irvine, UK) and relevant secondary antibodies (goat
anti-mouse Alexa 488 or -rabbit Alexa 594 (1:500 dilution; ThermoFisher, Paisley, UK) were
used. Nuclei were counterstained with DAPI (2.5 µg/mL) (Sigma-Aldrich, Irvine, UK).
Samples were visualised on a Zeiss LSM 800 confocal microscope. The mean fluorescence
intensity/µm2 (MFI) was extracted for repeat areas of each image captured using Zen 2.
Blue edition software (Carl Zeiss Microscopy GmbH, Jena, Germany).
4.6. RNA Extraction and Real Time PCR Analysis
Tissue (0.5 mm2) preserved in RNA Later (Life Technologies, Paisley, UK) was cut
into small pieces and added to re-enforced extraction vials containing 450 µL of Promega
™RNA lysis buffer (Promega, Southhampton, UK) prior to homogenisation using a bead-
beater. Tissue debris was collected following microfugation and RNA extracted using the
Nucleospin RNA 11 extraction kit (Bioline, London, UK) according to the manufacturer’s
instructions. Purified RNA was diluted to 350–400 ng/µL and cDNA was synthesised
as previously described [14]. Gene expression was quantified by Taqman real-time poly-
merase chain reaction (RT-qPCR) using primers (sourced from IDT, Leuven, Belgium)
targeting the following genes: CX26; CX30; CX43; Panx1, IL-6; IL17; TRL2; Ki67; and
GAPDH (Supplementary Table S1). The cycle threshold value (Ct value) was extracted and
normalised against the Ct of GAPDH (∆∆Ct method) [69], where ∆Ct = Ct target gene −
Ct GAPDH, ∆∆Ct = ∆Ct psoriatic tissue − ∆Ct normal tissue, Gene expression = 2−∆∆Ct.
Data is represented as the fold-increase of the mean value of the psoriatic tissue over the
control tissue. Gene fold changes ≥ ±2 were considered significant [25,69].
4.7. ELISA Assays and Cytokine Array
Supernatants were collected from NF and PF fibroblasts at passage 2, HaCaT cells
and NF before and after 24 h challenge with 10 µg/mL PGN. Samples were centrifuged
for 5 min, transferred to fresh tubes prior to storage at −70 ◦C. Interleukin-6 (IL-6) ELISA
(Quantikine® ELISA, RnDSystems, Abingdon, UK) were carried out following the manufac-
turer’s guidelines and previously described [14]. To determine the pro-inflammatory status
of the 3D organotypic models or NF following exposure to PGN and or Gap27 supernatants
were subject to RnD systems Human Cytokine Array Panel A kits (RnD Systems, Abingdon,
UK). Membranes were developed with streptavidin-horse radish peroxidase conjugate
and detected via chemiluminescence using an Odyssey FC Dual Mode imaging system
and LiCOR Image Studio software (LiCOR, Cambridge, UK). Data was calculated by dot
intensity analysis and background levels subtracted to permit relative pixel intensity (RPI)
to be extracted. Data are presented as the fold change in cytokine expression over control
samples.
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4.8. Statistical Analysis
All experiments were performed in triplicate and on at least three separate occasions
from at least three different donors. All values indicate the mean ± SEM and the num-
ber of independent experiments (N); data was compiled and statistically analysed using
appropriate tests for data sets (stated in figure legends) in GraphPad Prism 9 (GraphPad
software, USA; www.graphpad.com (accessed on 20 May 2021)) (* p < 0.05; ** p < 0.005,
*** p < 0.001).
Supplementary Materials: Supplementary Materials can be found at https://www.mdpi.com/
article/10.3390/ijms22116060/s1.
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